• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Inogen Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8/7/25 4:24:22 PM ET
    $INGN
    Industrial Specialties
    Health Care
    Get the next $INGN alert in real time by email
    8-K
    false0001294133Inogen Inc00012941332025-08-072025-08-07

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): August 07, 2025

     

     

    INOGEN, INC.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    001-36309

    33-0989359

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    859 Ward Drive

     

    Goleta, California

     

    93111

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: (805) 562-0500

     

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common Stock, $0.001 par value

     

    INGN

     

    The Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


    Item 2.02. Results of Operations and Financial Condition.

    On August 7, 2025, Inogen, Inc. (the "Company") issued a press release reporting its financial results for the second quarter ended June 30, 2025. A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K.

    The information set forth under this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such a filing.

    Item 9.01. Financial Statements and Exhibits.

    (d) Exhibits

     

    Exhibit

     

     Description

    99.1

    Press Release dated August 7, 2025.

    104

    The cover page of this Current Report on Form 8-K, formatted in Inline XBRL.


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

     

     

     

    INOGEN, INC.

     

     

     

     

    Date:

    August 7, 2025

    By:

    /s/ Michael Bourque

     

     

     

    Michael Bourque
    Executive Vice President
    Chief Financial Officer
    Treasurer
    (Principal Accounting and Financial Officer)

     


    Get the next $INGN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $INGN

    DatePrice TargetRatingAnalyst
    6/16/2025$14.00Buy
    B. Riley Securities
    5/22/2025$12.00Hold → Buy
    Needham
    2/15/2024Mkt Perform → Outperform
    William Blair
    8/8/2023$15.00 → $8.00Overweight → Neutral
    JP Morgan
    7/14/2023Buy → Hold
    Needham
    1/17/2023Outperform → Mkt Perform
    William Blair
    12/9/2021$47.00Hold → Buy
    Needham
    11/8/2021$70.00 → $40.00Hold
    Stifel
    More analyst ratings

    $INGN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Inogen Announces Second Quarter 2025 Financial Results

    Delivered strong top-line results; raising full year 2025 revenue expectations Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended June 30, 2025. Recent Highlights Achieved second quarter 2025 revenue of $92.3 million, a year-over-year increase of 4.0%, marking the sixth consecutive quarter of mid-single-digit percentage growth. Reported GAAP net loss of $4.2 million and adjusted net loss of $0.7 million. Delivered adjusted EBITDA of $2.1 million, the second consecutive quarter of positive adjusted EBITDA. Generated $4.4 million in operating

    8/7/25 4:05:00 PM ET
    $INGN
    Industrial Specialties
    Health Care

    Inogen to Report Second Quarter 2025 Financial Results on August 7, 2025

    Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it will report second quarter 2025 financial results after the market closes on Thursday, August 7, 2025. On the same day, the Company will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET. Individuals interested in listening to the conference call may do so by dialing: US domestic callers (877) 841-3961 Non-US callers (201) 689-8589 Please reference Inogen to join the call. A live audio webcast and archived recording of the conference call will be available to all interested parties through the News / Events page on the Inogen I

    7/17/25 8:30:00 AM ET
    $INGN
    Industrial Specialties
    Health Care

    Inogen Introduces Voxi 5 Stationary Oxygen Concentrator: Setting a New Standard in Affordable, Durable Oxygen Therapy

    Inogen, Inc. (Nasdaq: INGN), a leading medical technology company specializing in innovative respiratory products for homecare use, today announced the launch of VoxiTM 5, a new stationary oxygen concentrator (SOC) designed to enhance access to high-quality oxygen therapy for long-term care patients in the United States. As the latest addition to Inogen's product portfolio, Voxi 5 augments the company's line of portable oxygen concentrators, significantly expanding the market potential while leveraging existing sales channels. The Voxi 5 stationary oxygen concentrator combines affordability with durability, setting a new standard in oxygen therapy Developed in collaboration with Yuwell

    6/23/25 8:30:00 AM ET
    $INGN
    Industrial Specialties
    Health Care

    $INGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    B. Riley Securities initiated coverage on Inogen with a new price target

    B. Riley Securities initiated coverage of Inogen with a rating of Buy and set a new price target of $14.00

    6/16/25 7:50:27 AM ET
    $INGN
    Industrial Specialties
    Health Care

    Inogen upgraded by Needham with a new price target

    Needham upgraded Inogen from Hold to Buy and set a new price target of $12.00

    5/22/25 8:16:14 AM ET
    $INGN
    Industrial Specialties
    Health Care

    Inogen upgraded by William Blair

    William Blair upgraded Inogen from Mkt Perform to Outperform

    2/15/24 6:28:38 AM ET
    $INGN
    Industrial Specialties
    Health Care

    $INGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Wright Mary E claimed ownership of 12,180 shares (SEC Form 3)

    3 - Inogen Inc (0001294133) (Issuer)

    8/7/25 4:32:10 PM ET
    $INGN
    Industrial Specialties
    Health Care

    New insider Yi Boyer Jennifer M claimed ownership of 13,509 shares (SEC Form 3)

    3 - Inogen Inc (0001294133) (Issuer)

    8/7/25 4:31:08 PM ET
    $INGN
    Industrial Specialties
    Health Care

    Director Boehnlein Glenn S was granted 30,612 shares, increasing direct ownership by 66% to 76,885 units (SEC Form 4)

    4 - Inogen Inc (0001294133) (Issuer)

    5/19/25 8:53:23 AM ET
    $INGN
    Industrial Specialties
    Health Care

    $INGN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, CFO & Treasurer Bourque Michael J. was granted 48,225 shares, converted options into 25,000 shares, covered exercise/tax liability with 28,579 shares and bought $24,960 worth of shares (3,000 units at $8.32) (SEC Form 4)

    4 - Inogen Inc (0001294133) (Issuer)

    3/4/25 6:42:36 PM ET
    $INGN
    Industrial Specialties
    Health Care

    CEO and President Smith Kevin Raymond Merrill was granted 55,475 shares, converted options into 28,333 shares, covered exercise/tax liability with 39,797 shares and bought $100,245 worth of shares (11,709 units at $8.56), increasing direct ownership by 383% to 70,274 units (SEC Form 4)

    4 - Inogen Inc (0001294133) (Issuer)

    3/4/25 6:41:11 PM ET
    $INGN
    Industrial Specialties
    Health Care

    $INGN
    SEC Filings

    View All

    SEC Form 10-Q filed by Inogen Inc

    10-Q - Inogen Inc (0001294133) (Filer)

    8/8/25 4:11:21 PM ET
    $INGN
    Industrial Specialties
    Health Care

    Inogen Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Inogen Inc (0001294133) (Filer)

    8/7/25 4:24:22 PM ET
    $INGN
    Industrial Specialties
    Health Care

    Inogen Inc filed SEC Form 8-K: Leadership Update

    8-K - Inogen Inc (0001294133) (Filer)

    7/29/25 4:06:11 PM ET
    $INGN
    Industrial Specialties
    Health Care

    $INGN
    Financials

    Live finance-specific insights

    View All

    Inogen Announces Second Quarter 2025 Financial Results

    Delivered strong top-line results; raising full year 2025 revenue expectations Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended June 30, 2025. Recent Highlights Achieved second quarter 2025 revenue of $92.3 million, a year-over-year increase of 4.0%, marking the sixth consecutive quarter of mid-single-digit percentage growth. Reported GAAP net loss of $4.2 million and adjusted net loss of $0.7 million. Delivered adjusted EBITDA of $2.1 million, the second consecutive quarter of positive adjusted EBITDA. Generated $4.4 million in operating

    8/7/25 4:05:00 PM ET
    $INGN
    Industrial Specialties
    Health Care

    Inogen to Report Second Quarter 2025 Financial Results on August 7, 2025

    Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it will report second quarter 2025 financial results after the market closes on Thursday, August 7, 2025. On the same day, the Company will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET. Individuals interested in listening to the conference call may do so by dialing: US domestic callers (877) 841-3961 Non-US callers (201) 689-8589 Please reference Inogen to join the call. A live audio webcast and archived recording of the conference call will be available to all interested parties through the News / Events page on the Inogen I

    7/17/25 8:30:00 AM ET
    $INGN
    Industrial Specialties
    Health Care

    Inogen Announces First Quarter 2025 Financial Results

    Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended March 31, 2025. "Inogen's strong first quarter financial results underscore our success in driving improved commercial and operational execution," said Kevin Smith, President and Chief Executive Officer. "We are making great progress and remain committed to positioning the company for sustainable growth and profitability, while creating value for all stakeholders." First Quarter 2025 Financial Results Total revenue in the first quarter of 2025 was $82.3 million, an increase of 5.5% from the prior-year p

    5/7/25 4:05:00 PM ET
    $INGN
    Industrial Specialties
    Health Care

    $INGN
    Leadership Updates

    Live Leadership Updates

    View All

    Inogen Announces Appointment of Mira Kirti Sahney to Board of Directors and Retirement of Board Member Tom West

    Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Mira Kirti Sahney to Inogen's Board of Directors, effective January 31, 2025. The company also announced that Tom West, who has served as a director since April 2023, retired as a member of the Board of Directors, effective January 30, 2025. "We are thrilled to welcome Mira Sahney to the Inogen Board. Mira brings considerable management, technical, and operational experience in the medical device field to Inogen," said Elizabeth Mora, Chairperson of the Board. "Mira's appointment will further strengthen Inogen's Board with a

    2/3/25 4:00:00 PM ET
    $INGN
    $MDT
    $MYO
    Industrial Specialties
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus

    Sight Sciences Appoints MK Raheja as Executive Vice President, Research and Development and Brenton Taylor as Executive Vice President, Operations

    MENLO PARK, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences," or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, announced today the appointment of MK Raheja, Ph.D. as its Executive Vice President, Research and Development, and Brenton Taylor as its Executive Vice President, Operations, effective November 4, 2024. Sight Sciences also announced that Sam Park, its Chief Operating Officer, who oversaw both R&D and Operations, will be retiring from his role at the Company effective November 15, 2024, and will remain available as a con

    11/7/24 4:04:00 PM ET
    $INGN
    $SGHT
    Industrial Specialties
    Health Care
    Medical/Dental Instruments

    Inogen Appoints Eric Pauls as Vice President of Sales, North America

    Inogen, Inc. (NASDAQ:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Eric Pauls as Vice President of Sales, North America, effective September 3, 2024. Mr. Pauls joins Inogen from RQM+, where he served as Chief Customer Officer. Kevin Smith, President and Chief Executive Officer of Inogen said, "We are excited to welcome Eric to the Inogen team. With over 20 years of experience driving growth and leading high-performing teams in the respiratory care business, his leadership will be instrumental as we expand our product offerings and solutions for patients with respiratory conditions in the Uni

    9/5/24 8:30:00 AM ET
    $INGN
    Industrial Specialties
    Health Care

    $INGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Inogen Inc

    SC 13G/A - Inogen Inc (0001294133) (Subject)

    11/14/24 11:12:09 AM ET
    $INGN
    Industrial Specialties
    Health Care

    SEC Form SC 13G filed by Inogen Inc

    SC 13G - Inogen Inc (0001294133) (Subject)

    4/23/24 8:25:34 PM ET
    $INGN
    Industrial Specialties
    Health Care

    SEC Form SC 13G/A filed by Inogen Inc (Amendment)

    SC 13G/A - Inogen Inc (0001294133) (Subject)

    2/14/24 4:00:17 PM ET
    $INGN
    Industrial Specialties
    Health Care